A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Hyaluronic Acid; Ophthalmic Solutions; Tetrahydrozoline; Tofacitinib

Criteria

Inclusion Criteria:

• Subjective symptoms of dry eye for at least 6 months

• Signs of moderate to severe dry eye (corneal staining score and schirmer test without anesthesia)

Exclusion Criteria:

• Women who are nursing, pregnant or planning pregnancy during the study

• Participation in other studies within 30 days of screening visit

• Ocular disorders that may confound interpretation of study results